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3-Adrenoceptor
timulation on Top of
1-Adrenoceptor Blockade
Stop or Encore?”*
ean-Luc Balligand, MD, PHD
russels, Belgium
atecholamines released by the orthosympathetic system
lay a major role in the short- and long-term regulation of
ardiac function. Although acute stimulation of adrenergic
eceptors (ARs) (mostly 1) increases all aspects of cardiac
ontractility and is generally considered as positive for heart
unction, their prolonged activation results in adverse re-
odeling of the myocardium, in part due to toxic effects on
ardiomyocytes (and other cells composing cardiac muscle),
s exemplified by the cardiac phenotype of mice with
ardiac-specific overexpression of 1-AR (1). Accordingly,
hronic overactivation of the orthosympathetic system in
eart failure, albeit initially adaptive, is generally considered
o be deleterious in the long term (2). This is amply
upported by clinical evidence of the beneficial effect of
-adrenergic blockade in failing patients.
See page 1532
The mechanistic interpretation of this beneficial effect,
owever, is far from simple. Although the generic property
o antagonize 1-AR activation (thereby preventing its
ong-term deleterious effects) is shared by all blockers with
roven clinical efficacy, several characteristics have recently
merged as key factors to predict benefit (or absence
hereof). These include polymorphisms at -ARs (3–5) or
-protein receptor kinases regulating their desensitization
6), as well as ancillary pharmacodynamic properties of
pecific blockers.
Nebivolol belongs to the group of -blockers with proven
linical benefit in a population of heart failure patients, as
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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édérale (PAI-P6/55), the Communauté Française de Belgique (ARC 06/11-338),
nd Fonds National de la Recherche Scientifique.emonstrated in the SENIORS (Study of the Effects of
ebivolol Intervention on Outcomes and Rehospitalisation
n Seniors with Heart Failure) trial (7). It is endowed with
igh specificity for 1-AR antagonism (8). However, its
harmacodynamic properties extend beyond just 1-AR
lockade. Early work has identified ancillary properties as
erotonin 5-HT1A receptor or P2Y purinergic receptor (9)
gonist—at least in the kidney vasculature—2-AR agonist
10), or more recently, alpha-1-AR antagonist (11). Most of
hese properties, however, are based on observations in
eterologous expression systems (against recombinant re-
eptors) or animal tissues, raising doubt about their gener-
lizability to the drug’s effect on native human receptors in
itu. In a previous study on small resistance coronary vessels
rom human specimens, C. Dessy in our laboratory had
emonstrated vasodilating properties of nebivolol through
ctivation of the third isotype of beta-adrenoceptors, 3-
Rs (12).
3-ARs have classically been considered as receptors
ediating metabolic effects (e.g., lipolysis) in adipocytes,
lthough their low expression and lipolytic activity in (at
east normal) human white fat tissue has dampened enthu-
iasm for their exploitation as therapeutic targets of obesity
13). They raised renewed interest in the cardiovascular field
fter the discovery of their expression in human ventricular
yocardium (14). Surprisingly, in this tissue, their activa-
ion with preferential agonists (in the presence of combined
1- and 2-AR blockade) produced effects functionally
ntipathetic to those classically ascribed to the other 2
sotypes, (i.e., a decrease in developed cardiac muscle ten-
ion). This has been independently confirmed with similar
harmacologic approaches in ventricular cardiac tissues and
ells from a number of animal species (15,16). Accordingly,
ice with deletion of the 3-AR gene display an enhanced
notropic response to nonspecific -adrenoceptor ago-
ists (17), which could be interpreted as unopposed
timulation of the residual 1- and 2-ARs. Mechanis-
ically, this countervailing effect of 3-AR stimulation
as shown to involve G-alpha-i coupling to a nitric oxide
ynthase (NOS) activity (18), resulting in NO-mediated
ttenuation of 1- and 2-adrenergic effects on cardiac
uscle (Fig. 1).
Other distinctive properties of 3-ARs deserve further
onsideration in the context of cardiac diseases. Contrary to
1-AR (and to a lesser extent 2-AR), the abundance of
3-AR messenger ribonucleic acid (and proteins) increases
n ventricular myocardium from patients with heart failure
rom ischemic or dilated cardiomyopathies (19), as well as
epsis (20). Such paradoxical regulation is consistent with in
itro up-regulation of 3-ARs in rodent cardiomyocytes
hronically exposed to catecholamines (21), as well as
nimal models of diabetes (22), a condition also associated
ith hyperadrenergism. Also, 3-ARs are more resistantthan 1- and 2-ARs) to homologous desensitization (23).
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or an efficient pharmacologic modulation in the diseased
eart.
Building upon previous evidence for 3-AR agonism of
ebivolol in human vessels (12), Rozec et al. (24) in this
ssue of the Journal tested the ability of the drug to activate
imilar receptors in human myocardium. Using ventricular
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Figure 1 Putative Beneficial Effects of Combined Activation of
3-Adrenoceptors and Blockade of 1-Adrenoceptors o
Nebivolol combines the properties of a 1-adrenoceptor (AR) antagonist (1-blocke
lial cells of the coronary microvasculature and on cardiac myocytes. (Left) Activati
oxide synthase (NOS) and the release of nitric oxide (NO) and of an endothelium-d
and coronary perfusion. In addition, NO may paracrinally promote cardiomyocyte re
(Right) In ventricular cardiomyocytes, nebivolol combines the effects of 1-AR bloc
cardial remodeling, and activation of 3-AR; the latter, through G-alpha-i coupling,
lation of contractility. Hypothetically, agonism on 3-ARs may contribute to addition
sustained functional antagonism of the 1-AR/cyclic adenosine monophosphate (c
eling, ventricular perfusion and filling ultimately would result in improved LV functioiopsies from transplanted human hearts, they show a soncentration-dependent attenuation of developed contrac-
ion force with nebivolol, which replicates similar effects of
he preferential 3-AR agonist, BRL37344. This effect is
aintained despite coincubation with the 1- and 2-AR
locker, nadolol, ruling out the implication of these 2
sotypes; conversely, it is strongly inhibited by coincubation
ith a 3-AR antagonist, L-748,337. As in previous studies on
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a 3-AR agonist. In human myocardium, 3-ARs are expressed both on endothe-
3-ARs on coronary endothelium produces the activation of endothelial nitric
hyperpolarizing factor (EDHF), both of which contribute to increased vasodilation
n and left ventricular (LV) diastolic filling, thereby enhancing diastolic reserve.
which prevents the deleterious effects of chronic adrenergic stimulation on myo-
activation and NO production may oppose the acute effects of adrenergic stimu-
tection against adverse remodeling under chronic adrenergic stress through
pathway or other (yet undetermined) pathways. The combined effects on remod-
ure illustration by Rob Flewell.gon
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ediated activation of NO synthesis.
How do these findings bear on the clinical use of
ebivolol? First, it should be remembered that the authors
sed human myocardium from transplanted hearts, studied
n organ baths ex vivo. They have done an extensive
haracterization of this model in their earlier work (25),
ith contractile responsiveness consistent with inotropic
odulation in classical cardiac preparations; they also care-
ully excluded rejecting hearts. However, their in vitro
etting allows only limited prediction of the effect of similar
gonists in vivo; in particular, loading conditions cannot be
alibrated, and parameters such as relaxation cannot be
tudied accurately. Therefore, their observation of an atten-
ation of contractile tension with nebivolol may not necessarily
ranslate into a negative inotropic effect in vivo. Indeed, a
3-AR–mediated blunting of the positive inotropic effect of
atecholamines may abbreviate systolic contraction and in-
rease the length of diastolic interval, which together with NO
elease in the myocardium may promote relaxation, diastolic
lling, and subendocardial perfusion (26). The overall result
ould be an increased diastolic reserve and improved left
entricular function (Fig. 1).
The authors also selected myocardial samples from non-
ailing hearts. Although this allows some degree of analysis
f 3-AR effects in close to “normal” conditions, the
onclusions may not necessarily apply to the failing heart;
ndeed, heart failure induces dramatic changes in excitation–
ontraction coupling, tissue remodeling, and alterations in
ome key intracellular signaling elements, including NOS
xpression, NOS coupling, and NO bioavailability due to
ncreased oxidant stress. The latter, in particular, may
bliterate some of the NO-dependent effects reported here.
owever, in a previous study by Moniotte et al. (19), the
ffect of 3-AR agonists was somewhat attenuated, but still
resent in biopsies from failing compared with nonfailing
earts, and was relatively less desensitized than the 1- and
2-AR positive inotropic effect. This would support a
ersistent attenuation of the 1- and 2-AR effects by
3-AR stimulation (including with nebivolol) in failing
earts. In addition, Dessy et al. (27) showed that the
asodilatory effect of 3-AR stimulation in human coronary
icrovessels (300-m diameter) persisted despite deficient
O-mediated relaxation, due to alternative coupling to
ndothelium-derived hyperpolarizing factor (EDHF) va-
orelaxing mechanisms. Finally, nebivolol is endowed with
dditional antioxidant properties in vitro (28), which may
ranslate into additional protection against endothelial dys-
unction (29) and tissue remodeling in vivo. Overall, there is
good probability that the combination of 1-AR blockade
ith 3-AR agonism by nebivolol may similarly be opera-
ive on the failing heart. This is supported by the results of
n early clinical study with nebivolol on a limited number of
atients with ischemic cardiomyopathy (30). The putative
eneficial effect on diastolic reserve would have been par-
icularly suited for the improvement of heart failure inlderly patients, as included in the SENIORS study, be-
ause of the high prevalence of heart failure with normal left
entricular (LV) ejection fraction (and altered diastole) in
his population. Of interest, the effects observed in the
resent study were already apparent at nanomolar concen-
rations of nebivolol, which are probably close to therapeutic
evels in vivo.
Several important questions remain and call for some
nuances” to the above paradigms. More careful analysis
eeds to be done on the electrophysiological effects of
3-AR stimulation in (animal or human) cardiac cells, in
articular on the action potential and automaticity. Regional
ifferences probably exist for these effects (e.g., between
tria and ventricles). A recent study in human atrial cells
howed an increase in ICa-L with increased contractile
hortening in response to 3-AR stimulation (31), contrast-
ng with the effects on ventricular muscle reported here (to
he extent that isolated cell shortening can be compared
ith developed tension of whole, multicellular muscle tis-
ue; the protocol for pharmacologic characterization of a
3-AR pathway also differs significantly between the 2
tudies). Nevertheless, there are precedents for such differ-
nces at the atrial level, particularly for the effects of NO
32). The effect of 3-AR stimulation on heart rate is also
ifficult to predict; in vivo, infusion of 3-AR agonists
esulted in cardiac acceleration, but this was mainly due to
aroreflex tachycardia secondary to systemic vasodilatation
33). In the case of nebivolol, this would be counteracted by
1-AR blockade.
As importantly, the effect of long-term stimulation of
ardiac 3-ARs on remodeling needs to be carefully exam-
ned. Chronic overexpression of 1-AR in transgenic mice
esults in the development of dilated cardiomyopathy, as
entioned previously (1). If 3-ARs antagonize the effects
f 1-AR stimulation, as proposed in the preceding text, the
rediction would be that long-term 3-AR stimulation
ould protect against adverse remodeling (Fig. 1). This is
upported by observations on the phenotype of transgenic
ice with cardiac-specific overexpression of 3-ARs under
hronic catecholaminergic stress (34). Such a protective
echanism may also participate in the supplemental pro-
ection afforded by nebivolol (vs. metoprolol) in post-
nfarction remodeling (35).
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